Hello, Fool! | Login | Signup | My Fool
Dec 4, 2008 11:59 AM ET | Feedback | Site Changes | Help
A biotechnology company focused on the development and commercialization of innovative therapeutic products for patients with chronic and life-threatening cardiovascular, cancer and infectious diseases.
View All Commentary (UTHR)
Recs
cnbr1 (59.42) Submitted: 10/04/06 9:44 AM : Start Price: $51.25 UTHR Score: -37.38
New PAH drugs will reduce UTHR's market; generic Flolan, Ambrisentan etc.
Report this Post Replies: 0 | Reply | Permalink
Oops! There appears to be a problem with your comment. Check to see if there's something you left out.
Terms & Conditions
RSS Headlines
Fool UK